[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345555-105":3,"detail-sidebar-cat-0-en-105":79,"doc-detail-345555-en":129},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":72,"head_meta":74,"extra_data":76,"updated_unix":78},105,"en","divergent-effects-of-pla2g7-on-prostate-cancer-biochemical-recurrence-in-european-american-and-african-american-men","Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men","","Identification and characterization of prostate tumor markers differentially expressed between European American (EA) and African American (AA) men is central to understanding prostate cancer disparities, yet validation and recurrence-risk implications remain limited. This study evaluates PLA2G7 using EA and AA prostate cancer surgical specimens in a nested case-control framework adjusting for age, stage, and Gleason, then re-analyzes a combined dataset. Results show tumor PLA2G7 predicts divergent biochemical recurrence risk by self-reported race, while noncancer tissues show no prognostic value.",{"@graph":14,"@context":71},[15,34,54],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/divergent-effects-of-pla2g7-on-prostate-cancer-biochemical-recurrence-in-european-american-and-african-american-men/345555/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":48,"encodingFormat":47,"isAccessibleForFree":49,"interactionStatistic":50},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/divergent-effects-of-pla2g7-on-prostate-cancer-biochemical-recurrence-in-european-american-and-african-american-men/345555.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-22",true,{"@type":51,"interactionType":52,"userInteractionCount":22},"InteractionCounter",{"@type":53},"ViewAction",{"@type":55,"mainEntity":56},"FAQPage",[57,63,67],{"name":58,"@type":59,"acceptedAnswer":60},"What marker does the study focus on and why?","Question",{"text":61,"@type":62},"The study focuses on phospholipase A2 group 7 (PLA2G7) because it may function as a prostate tumor marker whose expression differs between European American and African American men and could help clarify recurrence-risk disparities.","Answer",{"name":64,"@type":59,"acceptedAnswer":65},"How was PLA2G7 evaluated in the study?",{"text":66,"@type":62},"PLA2G7 protein prognostic value was assessed using prostate cancer surgical specimens from EA and AA patients in a nested case-control design controlling for age, stage, and Gleason, followed by re-analysis of a published dataset.",{"name":68,"@type":59,"acceptedAnswer":69},"What was the key finding about recurrence risk across racial groups?",{"text":70,"@type":62},"Higher tumor-specific PLA2G7 expression was linked to lower biochemical recurrence risk in EA men but to elevated recurrence risk in AA men, indicating opposite prognostic effects by self-reported race/ethnicity.","https://schema.org",{"og:url":32,"og:type":73,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":75,"canonical":32},"index,follow",{"doc_id":77,"site_id":7},345555,1790101894,{"code":4,"msg":80,"data":81},"success",[82,86,90,94,99,104,109,113,118,121,125],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":83,"show_sort_weight":84,"slug":85},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":87,"show_sort_weight":88,"slug":89},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},"Exam",70,"exam",{"id":95,"doc_module":4,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},5,"Comic",60,"comic",{"id":100,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},6,"Technology",50,"technology",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},7,"Healthcare",40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":111,"slug":112},8,30,"research-report",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},9,"Religion & Spirituality",20,"religion-spirituality",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":116,"slug":120},"World Cup","world-cup",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":122,"slug":124},10,"Lifestyle","lifestyle",{"id":126,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":95,"slug":128},19,"General","general",{"code":4,"msg":80,"data":130},{"doc_id":77,"user_id":131,"nickname":42,"user_avatar":132,"doc_module":4,"category_id":110,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","JNCI: Journal of the National Cancer Institute, 2026, 118(6), 1097–1107  \n[https://doi.org/10.1093/jnci/djag036](https://doi.org/10.1093/jnci/djag036)  \nAdvance Access Publication Date: March 13, 2026  \nArticle  \nDivergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men  \nChanning J. Paller , MD1, 2,‡, Shuanzeng Wei , MD, PhD3,‡, Megan Schumacher , MS2, Daniel Rabizadeh , MS2, Yu-Ching Hsu, PhD2, Changxue Lu , PhD2, Yidong Chen, PhD4, Yuezhou Jing, MS2, Bruce J. Trock , PhD2,  \nMayuko Kanayama , MD, PhD2, Stefan Ambs , PhD, MPH5, Diana M. Stafforini , PhD6, William B. Isaacs , PhD2, George J. Netto , MD7, Tamara L. Lotan , MD1, 2,8, Angelo M. De Marzo , MD, PhD1, 2,8, Elizabeth A. Platz , ScD, MPH1, 2,9, Jun Luo , PhD1, 2, 􀀃  \n1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA 2Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA 3Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA  \n4Department of Population Health Sciences, the University of Texas Health San Antonio, San Antonio, TX, USA 5Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA 6Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA  \n7Department of Pathology and Lab Med, University of Pennsylvania, Philadelphia, PA, USA 8Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA 9Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA  \n􀀃 Corresponding author: Jun Luo, PhD, Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA ([jluo1@jhmi.edu](jluo1@jhmi.edu)) .  \n‡These authors contributed equally  \nAbstract  \nBackground: Identification and characterization of prostate tumor markers differentially expressed in European American (EA) men vs African American (AA) men has been one of the focus areas positioned to understand and address prostate cancer disparity in the US. Whereas some genes are differentially expressed, validation studies are limited, and the impact of these expression differenceson recurrence risk remains unclear.  \nMethods: This study focused on phospholipase A2 group 7 (PLA2G7) in prostate cancer surgical specimens from EA and AA patients. A nested case-control study was conducted to evaluate the prognostic value of the PLA2G7 protein while controlling for age, stage, and Gleason, followed by re-analysis of a published dataset of 556 EA and 596 AA prostate cancer patients. Expression signatures correlated with PLA2G7 were investigated in both patient populations.  \nResults: PLA2G7 was more frequently overexpressed in EA tumors than AA tumors, and higher tumor-specific PLA2G7 expression was associated with divergent outcomes: lower biochemical recurrence risk in EA men but elevated risk in AA men. Expression in noncancer tissues showed no prognostic value. Whereas androgen response signatures were consistently enriched in high-PLA2G7 tumors across both groups, immune and inflammatory response gene sets showed opposite enrichment trends between AA and EA men.  \nConclusion: This study represents the first identification and validation of a tumor-specific marker that is both differentially expressed between prostate cancers in AA and EA men and demonstrates opposite prognostic effects based on self-reported race/ ethnicity. The findings emphasize the importance of evaluating prostate tumor markers across diverse geographic ancestries.  \nIntroduction  \nDisparities in prostate cancer in the United States are noteworthy, with African American (AA) men having incidence rates 1.8 times as high as European American (EA) men and mortality more than twice as high.1 Unequ","cbCaiasDj4gybf4Q","https://ap.wps.com/l/cbCaiasDj4gybf4Q","pdf",1792636,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What marker does the study focus on and why?\",\"answer\":\"The study focuses on phospholipase A2 group 7 (PLA2G7) because it may function as a prostate tumor marker whose expression differs between European American and African American men and could help clarify recurrence-risk disparities.\"},{\"question\":\"How was PLA2G7 evaluated in the study?\",\"answer\":\"PLA2G7 protein prognostic value was assessed using prostate cancer surgical specimens from EA and AA patients in a nested case-control design controlling for age, stage, and Gleason, followed by re-analysis of a published dataset.\"},{\"question\":\"What was the key finding about recurrence risk across racial groups?\",\"answer\":\"Higher tumor-specific PLA2G7 expression was linked to lower biochemical recurrence risk in EA men but to elevated recurrence risk in AA men, indicating opposite prognostic effects by self-reported race/ethnicity.\"}]","Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men | PDF",1790058074,28]